GENE ONLINE|News &
Current Challenges and Future Opportunities of Artificial RNA Editing – An Interview with Professor Toshifumi Tsukahara
With two COVID-19 vaccines gaining emergency use approvals, mRNA technology has come into focus over the past year. RNA technology encompasses a wide range of modalities and RNA editing is one among them. Although the technique is still being perfected and hasn’t become clinically viable, its high efficiency and safety over DNA editing is expected to make a splash in the near future.
We interviewed Professor Toshifumi Tsukahara, an expert in RNA editing to know more about the current challenges and future opportunities in the field.
We interviewed Professor Toshifumi Tsukahara, an expert in RNA editing to know more about the current challenges and future opportunities in the field.
It's free! Log in now to read
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
